Form 4: XBiotech Inc. Director W. Thorpe McKenzie Acquires Stock Options

Director W. Thorpe McKenzie was granted nonstatutory stock options to purchase 37,500 shares of XBiotech Inc.'s common stock on June 20, 2024.

Summary

• On June 20, 2024, W. Thorpe McKenzie, a director of XBiotech Inc., was granted nonstatutory stock options to purchase 37,500 shares of the company's common stock.
• The exercise price of the options is $5.12 per share, which is equal to the closing sales price of the shares on the grant date.
• The options vest in two equal portions at six months and one year from the grant date, and they expire ten years from the grant date.
• Following the transaction, McKenzie directly owns 37,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a transaction. The granting of stock options is generally viewed as a positive sign, but it's a routine event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The granting of stock options could potentially increase shareholder value if the director is incentivized to improve company performance.

Key Dates